Drugs / RVT-1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03924154 | Aug 2019 → Feb 2020 | pulmonary arterial hypertension | Altavant Sciences GmbH | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVT-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03924154 ↗ |
| Route | Oral | “administered orally” NCT03924154 ↗ |